First published 9/30/2026, 5:00:15 PM · Last updated 9/30/2026, 5:00:15 PM

Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition

Journal article published by Frontiers Media SA on 2026-09-30 about personalized anticoagulant therapy for venous thromboembolism, covering direct oral anticoagulants, unmet clinical needs, and Factor XI inhibition. No additional event details or outcomes were included in the supplied source excerpt.

Categories: public-health, science-and-space, positive-progress

Generated scores

Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.

Confidence: 2/10How certain the assessment is based on the clarity and evidence in the cited reporting.
Geographic reach: 1/10How widely the event reaches, from a local area (1) to worldwide impact (10).
Global importance: 2/10The event's broader significance, from limited importance (1) to major global importance (10).
Impact magnitude: 2/10The scale or severity of the real-world impact, from minor (1) to extreme (10).
Positivity: 6/10How harmful or beneficial the event is, from strongly harmful (1) to strongly positive (10).
Urgency: 2/10How time-sensitive the event is, from low urgency (1) to immediate attention needed (10).

Why it matters

The article addresses clinical gaps and potential future therapeutic strategies for venous thromboembolism.

Sources

Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition

Report an issue